Moleculin Biotech Inc. | Ownership
Companies that own Moleculin Biotech Inc.
The Vanguard Group, Inc.
660,458
2.46%
114,036
0%
06/30/2018
Geode Capital Management LLC
126,497
0.47%
40,907
0%
06/30/2018
Taylor, Cottrill, Erickson & Associates, Inc.
97,000
0.36%
0
0.03%
06/30/2018
CIBC World Markets, Inc.
94,850
0.35%
30,000
0%
06/30/2018
Sterling Capital Management LLC
90,000
0.34%
0
0%
06/30/2018
BlackRock Fund Advisors
46,648
0.17%
46,648
0%
06/30/2018
Bank of America, NA (Private Banking)
25,000
0.09%
0
0%
06/30/2018
Northern Trust Investments, Inc.
22,918
0.09%
9,406
0%
06/30/2018
Commonwealth Equity Services, Inc.
22,000
0.08%
5,500
0%
06/30/2018
Wetherby Asset Management, Inc.
19,792
0.07%
0
0%
06/30/2018
| Address |
5300 Memorial Drive
Houston Texas 77007
United States
|
|
Employees
|
- |
| Website |
http://www.moleculin.com |
| Updated |
07/08/2019 |
| Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. |
